Capricor Therapeutics has filed a lawsuit against Nippon Shinyaku and its U.S. subsidiary NS Pharma over a dispute tied to the future commercialisation of experimental Duchenne muscular dystrophy therapy Deramiocel.

A U.S. appeals court hearing over Medicare drug price negotiations has added to mounting pressure on pharmaceutical companies challenging the Inflation Reduction Act’s pricing regime.

During oral arguments before the D.C. Circuit, judges appeared sceptical of arguments brought by Teva Pharmaceuticals over how regulators classify medicines for Medicare price negotiations.

Alto Neuroscience is seeking to dismiss an investor lawsuit accusing the psychiatric biotech company of overstating the prospects of its lead depression drug candidate, Alto-100.

According to investors, the trial was negatively affected by patients who falsely reported taking the medication, raising questions about the reliability of the results and the company’s earlier public statements about the drug’s prospects.

A French court has handed Millennium Pharmaceuticals, Janssen and Cilag a partial victory in their ongoing dispute with several generic drugmakers over the cancer treatment Velcade, allowing the case to move forward on the question of damages.

The FDA is intensifying enforcement against misleading pharmaceutical advertising, particularly online promotions, and recently issued a cease-and-desist letter to Alnylam Pharmaceuticals over claims made about Amvuttra, a drug for ATTR-CM.

A Pennsylvania federal court has delivered a mixed ruling in a major generics antitrust case, allowing key claims to proceed against Novartis and its former subsidiary Sandoz, while dismissing others.

Sun Pharmaceutical Industries has secured interim relief from the Bombay High Court in a trademark dispute, strengthening its position in protecting branded pharmaceutical products.

The court restrained United Biotech from using any mark identical or deceptively similar to Sun Pharma’s “Octride.”

California’s highest court is weighing a case that could reshape how far pharmaceutical companies are expected to go in developing improved medicines, with early signals suggesting caution around imposing a legal “duty to innovate.”

For a company that not so long ago was the most valuable in Europe, Novo Nordisk has spent the past year looking unusually mortal. Its share price has shed 30% over twelve months. Its forecasts have been cut.

Faron Pharmaceuticals, the Finnish clinical-stage immunotherapy group, has terminated its liquidity provision agreement with Lago Kapital, citing improved natural trading activity in its shares — a notable signal of the dual-listed biotech's gradually strengthening profile in the public markets.

Shares in Arrowhead Pharmaceuticals rose 6.8 per cent on Wednesday after Australia's medicines regulator approved the US biotech's plozasiran therapy for an ultra-rare genetic disorder, expanding the geographic footprint of one of the most strategically important assets in the company's RNA interference pipeline.

The $7.4bn settlement between OxyContin manufacturer Purdue Pharma, its Sackler family owners and US states has taken legal effect, marking a long-awaited resolution to one of the most consequential corporate liability cases in modern American history and clearing the way for the disbursement of recovery funds to communities ravaged by the opioid crisis.

Jazz Pharmaceuticals will report first-quarter results after the US market closes on Tuesday, with investors weighing the Dublin-headquartered drugmaker's recent commercial trajectory against the buoyant tone struck by larger pharmaceutical peers earlier in the earnings season.

Alnylam Pharmaceuticals, the US biotech that has long been the standard-bearer for the RNA interference therapeutic class, has swung to a quarterly profit on the back of a surge in product sales, marking a watershed for a company whose unprofitable history has long unnerved more conservative investors.

AstraZeneca has announced a £300 million investment in the UK, marking a reversal after previously pausing major projects. 

A Philadelphia jury has begun deliberating in a medical malpractice case concerning the 2019 death of 26-year-old Matthew Tarnopol. 

Novo Nordisk has asked a Texas federal court to dismiss an antitrust lawsuit alleging it attempted to limit competition in the GLP-1 weight-loss drug market. 

India-based Sun Pharmaceutical Industries Ltd. has agreed to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion. 

An April 2026 executive order from Donald Trump introduces major changes to how psychedelic drugs could be reviewed and accessed in the U.S. The policy creates two new pathways: a faster U.S. Food and Drug Administration review process using Commissioner’s National Priority Vouchers and expanded early access through the Right to Try Act. 

New tariffs introduced by Donald Trump in April 2026 create significant legal and compliance challenges for pharmaceutical companies. The policy imposes tariffs of up to 100% on patented drugs and related ingredients under Section 232 of the Trade Expansion Act but includes multiple exceptions that complicate how the rules apply in practice.